A Major Step in Molecular Simulation - Key to Designing New Drugs

Researchers at Hospital del Mar Research Institute (IMIM) and Pompeu Fabra University (UPF) have successfully reproduced and reconstructed the complete process of a small molecule binding with its target protein. IMIM and UPF are part of the VPH NoE Network and this project started as part of the VPH NoE's Seed Exemplar Project 4.

This advance enables the calculation of the binding affinity and binding timescale as well as understanding the interactions established by the drug in order to act, thus moving towards safer and more efficient design of new drugs. This groundbreaking project helps show a process that was hitherto invisible and therefore unknown, and opens up a new avenue in the design of new drugs.

The binding process of a drug, usually a small molecule, to its target protein is highly dynamic and depends on interactions at a nanometric scale (billions of times smaller than a metre) and occurs at timescales of nano/micro-seconds (billions of times faster than a second). The capturing of movements of small molecules with a resolution of up to an atom is beyond current technical capabilities. However, using computer techniques, it is possible to represent the molecules at atomic scale and reproduce their movements with high mathematical precision.

Understanding how protein and molecules bind - in which the latter causes a biological response after being recognised by the former (binding) - is vitally important for the design of new drugs. Despite the progress made so far with the technique, no study had provided a complete reconstruction of the protein-ligand binding process. "The method provides not only the binding affinity and the kinetics of the reaction, but also information about the atomic resolution during the process: binding sites, transition states and metastable states are potentially useful for expanding the probability of success when designing drugs. This methodology can be directly applied to other molecular systems and is therefore of general interest in biomedical and pharmaceutical research" explains Gianni de Fabritiis, coordinator of the Computational Biophysics Laboratory of the Biomedical Computer Research Programme (GRIB) run by Hospital del Mar Research Institute (IMIM) and Pompeu Fabra University (UPF).

The researchers are now working to expand the applicability of this methodology and make better use of the computational capabilities as, in cases in which ligands are larger and more flexible and where the proteins involve more complex binding processes, greater computational effort is required.

For further information please see the reference article: "Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations" IBuch, T Giorgino, G De Fabritiis. www.pnas.org/content/early/2011/05/31/1103547108.abstract

Most Popular Now

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

New AI Transforms Radiology with Speed, …

A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...